Literature DB >> 8814610

Binding constants determined from Ca2+ current responses to rapid applications and washouts of nifedipine in frog cardiac myocytes.

P F Méry1, L Hove-Madsen, J L Mazet, R Hanf, R Fischmeister.   

Abstract

1. A fast perfusion system was used to analyse the kinetics of the response of L-type calcium current (ICa) to rapid applications and washouts of the dihydropyridine antagonist nifedipine in whole-cell patch-clamped frog ventricular myocytes. 2. Both the inhibition of ICa induced by nifedipine and the recovery from inhibition upon washout of the drug behaved as mono-exponential functions of time. 3. During application or washout of 100 nM nifedipine, only the peak amplitude of ICa varied but not its time course of activation or inactivation. 4. The rate constant of the onset of ICa inhibition increased with the concentration of nifedipine. However, the time course of the recovery from inhibition was independent of drug concentration. 5. Both rate constants were strongly sensitive to the holding potential but insensitive to the test potential. 6. Using simple rate equations and a one-binding-site analysis it was possible to determine the rate constants for association (k1) and dissociation (k-1) and the equilibrium dissociation constant (KD) of the reaction between nifedipine and Ca2+ channels. KD values for nifedipine were identical to IC50 values obtained from classical steady-state experiments. 7. With depolarized holding potentials, KD decreased strongly due to a large reduction in k-1 and a modest increase in k1. Assuming that these changes result from the distribution of Ca2+ channels between resting and inactivated states, a low-affinity binding to the resting state (R) and a high-affinity binding to the inactivated state (I) were obtained with the binding constants: k1R = 1.0 x 10(6) M-1 S-1, k-1R = 0.077 S-1, and KDR = 77 nM for the resting state; k1I = 4.47 x 10(6) M-1 S-1, k-1I = 7.7 x 10(-4) S-1, and KDI = 0.17 nM for the inactivated state. 8. Rapid application/washout experiments provide a unique way to determine, in an intact cell and in a relatively short period (2-4 min), the binding rate constants and the KD value of the reaction between a dihydropyridine antagonist and the Ca2+ channels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814610      PMCID: PMC1160618          DOI: 10.1113/jphysiol.1996.sp021479

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  38 in total

Review 1.  Receptor sites for Ca2+ channel antagonists.

Authors:  W A Catterall; J Striessnig
Journal:  Trends Pharmacol Sci       Date:  1992-06       Impact factor: 14.819

2.  Modulation of calcium channels in arterial smooth muscle cells by dihydropyridine enantiomers.

Authors:  S Hering; A D Hughes; E N Timin; T B Bolton
Journal:  J Gen Physiol       Date:  1993-03       Impact factor: 4.086

3.  Evidence for an external location of the dihydropyridine agonist receptor site on smooth muscle and skeletal muscle calcium channels.

Authors:  C Strübing; S Hering; H Glossmann
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

4.  Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.

Authors:  S Salomone; T Godfraind
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

5.  Subunit-dependent modulation of recombinant L-type calcium channels. Molecular basis for dihydropyridine tissue selectivity.

Authors:  A Welling; Y W Kwan; E Bosse; V Flockerzi; F Hofmann; R S Kass
Journal:  Circ Res       Date:  1993-11       Impact factor: 17.367

6.  Effect of dihydropyridines on calcium channels in isolated smooth muscle cells from rat vena cava.

Authors:  J Mironneau; T Yamamoto; I Sayet; S Arnaudeau; L Rakotoarisoa; C Mironneau
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

7.  Effects of diltiazem and verapamil on (+)-PN 200-110 binding kinetics in dog cardiac membranes.

Authors:  K Miwa; Y Miyagi; E Araie; S Sasayama
Journal:  Eur J Pharmacol       Date:  1992-04-22       Impact factor: 4.432

8.  The action of amlodipine on voltage-operated calcium channels in vascular smooth muscle.

Authors:  A D Hughes; S Wijetunge
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

9.  Frequency- and potential-dependency of the negative inotropic action of various dihydropyridine and non-dihydropyridine calcium antagonists.

Authors:  S Herzig; H Lüllmann; H Sieg
Journal:  Pharmacol Toxicol       Date:  1992-09

10.  Block of L-type calcium channels by charged dihydropyridines. Sensitivity to side of application and calcium.

Authors:  R S Kass; J P Arena; S Chin
Journal:  J Gen Physiol       Date:  1991-07       Impact factor: 4.086

View more
  5 in total

1.  Relationship between L-type Ca2+ current and unitary sarcoplasmic reticulum Ca2+ release events in rat ventricular myocytes.

Authors:  M L Collier; A P Thomas; J R Berlin
Journal:  J Physiol       Date:  1999-04-01       Impact factor: 5.182

2.  Effect of nifedipine on depolarization-induced force responses in skinned skeletal muscle fibres of rat and toad.

Authors:  G S Posterino; G D Lamb
Journal:  J Muscle Res Cell Motil       Date:  1998-01       Impact factor: 2.698

3.  A method for making rapid changes of superfusate whilst maintaining temperature at 37 degrees C.

Authors:  A J Levi; J C Hancox; F C Howarth; J Croker; J Vinnicombe
Journal:  Pflugers Arch       Date:  1996-09       Impact factor: 3.657

4.  Barnidipine block of L-type Ca(2+) channel currents in rat ventricular cardiomyocytes.

Authors:  J W Wegener; H Meyrer; J Rupp; H Nawrath
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

5.  Characterisation of marrubenol, a diterpene extracted from Marrubium vulgare, as an L-type calcium channel blocker.

Authors:  Sanae El-Bardai; Maurice Wibo; Marie-Christine Hamaide; Badiaa Lyoussi; Joelle Quetin-Leclercq; Nicole Morel
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.